Gabapentin Systematic (IUPAC) name 2-[1-(aminomethyl)cyclohexyl]acetic acid Clinical data Licence data US FDA: Pregnancy cat. B1(AU) C(US) Legal status POM (UK) ℞-only (US) ℞ Prescription only Routes Oral Pharmacokinetic data Bioavailability Rapid, in part by saturable carrier-mediated L-amino acid transport system Protein binding Less than 3% Metabolism Not appreciably metabolized Half-life 5 to 7 hours Excretion Renal Identifiers CAS number ATC code N03 PubChem DrugBank ChemSpider UNII KEGG ChEMBL Chemical data Formula C9H17NO2 Mol. mass 171.237 g/mol SMILES & (what is this?)
Gabapentin (brand names Fanatrex, Gabarone, Gralise, Neurontin, Nupentin) is a pharmaceutical drug, specifically a GABA analogue. It was originally developed for the treatment of epilepsy, and currently is also used to relieve neuropathic pain. There are, however, concerns regarding the quality of the trials conducted.
- 1 Medical uses
- 2 Adverse effects
- 3 Pharmacology
- 4 Society and culture
- 5 Veterinary use
- 6 References
- 7 External links
Gabapentin is used primarily for the treatment of seizures, neuropathic pain, and hot flashes. There are, however, concerns regarding the quality of the research on its use to treat migraines, bipolar disorders, and pain.
Gabapentin provides significant pain relief in about a third of people who take it for fibromyalgia or chronic neuropathic pain. It is also effective in reducing narcotic usage post operatively and is helpful in neuropathic pain due to cancer. It has not been shown to be useful for HIV associated sensory neuropathy. When used for neuropathic pain it does not appear superior to carbamazepine. Further evidence is needed to determine if it is effective for migraine prevention. It appears to be equally effective as pregabalin and is of lower cost. It does not appear to be of benefit in treating complex regional pain syndrome.
Gabapentin is approved for treatment of focal seizures in a number of countries and evidence supports it use for treating partial and mixed seizure disorders however there is insufficient evidence for it use in generalized epilepsy. There is little data to support its initial use over older anticonvulsant medication for any type of seizure disorder.
There is some evidence of benefit in acquired pendular nystagmus and infantile nystagmus but not in periodic alternating nystagmus. Gabapentin may help with menopausal symptoms. It may be effective in reducing pain and spasticity in multiple sclerosis. Gabapentin has been used to treat some symptoms of opiate withdrawal, but tests for smoking cessation treatment have had mixed results.
Gabapentin has been prescribed in the mental health context. Numerous trials show that it is not effective as a mood-stabilizing treatment for bipolar disorder and so has no therapeutic advantage in having fewer side-effects over better established bipolar drugs such as lithium and valproic acid. Gabapentin has limited usefulness in the treatment of anxiety disorders such as social anxiety disorder and obsessive-compulsive disorder, in treatment-resistant depression, and for insomnia. Gabapentin can also cause weight gain.
Gabapentin's most common side effects in adult patients include dizziness, drowsiness, and peripheral edema (swelling of extremities); these mainly occur at higher doses in the elderly. Also, children 3–12 years of age were observed to be susceptible to mild-to-moderate mood swings, hostility, concentration problems, and hyperactivity. Although rare, there are several cases of hepatotoxicity reported in the literature. Gabapentin should be used carefully in patients with renal impairment due to possible accumulation and toxicity.
An increase in formation of adenocarcinomas was observed in rats during preclinical trials; however, the clinical significance of these results remains undetermined. Gabapentin is also known to induce pancreatic acinar cell carcinomas in rats through an unknown mechanism, perhaps by stimulation of DNA synthesis; these tumors did not affect the lifespan of the rats and did not metastasize.
Gabapentin has been associated with an increased risk of suicidal acts or violent deaths. In 2009, the FDA issued a warning of an increased risk of depression and suicidal thoughts and behaviors in patients taking gabapentin, along with other anticonvulsant drugs modifying the packaging insert to reflect this. In July 2009, the manufacturer of gabapentin (Pfizer) went to trial regarding the association between gabapentin and the increased risk of suicide.
Gabapentin should not be discontinued abruptly after long term use. Abrupt or over rapid withdrawal may provoke a withdrawal syndrome reminiscent to alcohol or benzodiazepine withdrawal. Gradual reduction over a period of weeks or months helps minimize or prevents the withdrawal syndrome.
Side effects upon discontinuation of gabapentin that have been reported in medical literature include insomnia, restlessness, agitation, anxiety, disorientation, confusion, light sensitivity, diaphoresis, headaches, palpitations, hypertension, chest pain, and flu-like symptoms. In at least one case, abrupt cessation of a high dose of gabapentin triggered a seizure in an individual with no history of epilepsy.
Persons who accidentally or intentionally ingested overdoses have manifested drowsiness, blurred vision, slurred speech and somnolence or coma. Serum gabapentin concentrations may be measured to confirm diagnosis.
One possible mechanism of action, reported by Ben Barres of Stanford University and colleagues in Cell in 2009, was that gabapentin halts the formation of new synapses. Gabapentin binds to the α2δ subunit (1 and 2) and has been found to reduce calcium currents after chronic but not acute application via an effect on trafficking of voltage-dependent calcium channels in the central nervous system. This effect on calcium channel trafficking is another possible mechanism of action of gabapentin, but the exact mechanism remains in dispute.
Parke-Davis developed a drug called pregabalin to be a successor of gabapentin. Pregabalin was brought to market by Pfizer as Lyrica after the company acquired Warner-Lambert. Pregabalin is related in structure to gabapentin and is approved for treatment of epilepsy, neuropathic pain associated with diabetes, fibromyalgia, post-herpetic neuralgia, and generalized anxiety disorder. Compared to gabapentin, pregabalin is more potent, absorbs faster and has greater bioavailability. Higher potency means that less of the medication is required for the same effect. This does not necessarily result in fewer side effects. Another new drug atagabalin has been trialled by Pfizer as a treatment for insomnia. One must remain skeptical of industry run trials as, despite significant monetary damages awarded in trials discussed below, there is no certainty the company is not still suppressing negative or equivocal data and news reports indicate this may be the case with pregabalin as well.
Society and culture
In December 2004, the FDA granted final approval to a generic equivalent to Neurontin made by the Israeli firm Teva.
Neurontin is one of Pfizer's best-selling drugs, and was one of the 50 most-prescribed drugs in the United States in 2003. However, Pfizer has come under heavy criticism and serious litigation for its marketing of Neurontin, facing allegations that, behind the scenes, Parke-Davis marketed the drug for at least a dozen supposed uses for which the drug had not been FDA approved. Today it is a mainstay drug for migraines, even though it was not approved for such use in 2004.
Gabapentin was originally approved by the U.S. Food and Drug Administration (FDA) in 1994 for use as an adjunctive medication to control partial seizures (effective when added to other antiseizure drugs). In 2002, an indication was added for treating postherpetic neuralgia (neuropathic pain following shingles).
Numerous cases have been brought against the makers of Neurontin, with convictions arising not only for the illegal promotion of off-label uses. Much of the popular use of Neurontin among physicians stems from the widespread illicit marketing that Pfizer was convicted of, which was communicated via promotional messages through advisory boards, consultants’ meetings, and accredited continuing medical education events posing as independent third-party organizations, co-opting opinion leaders, educational enterprises and academia in their marketing campaign. The convictions for fraud set a new standard that goes beyond “scientific misconduct” and elevates the seriousness of the suppression of negative or unsupportive evidence as a form of fraud. As part of a case (CIVIL ACTION NO. 04-cv-10739-PBS) brought by Kaiser Foundation Health Plan against Pfizer, it was noted that "The general neuropathic pain indication cannot be granted for Neurontin based on the clinical trials in painful diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN)."
While it is often prescribed off-label (that is, at the discretion of a physician) for various conditions, this use is probably frequently due to the widespread illicit marketing Pfizer was convicted of, which was communicated via promotional messages through advisory boards, consultants’ meetings, and accredited continuing medical education events posing as independent third-party organizations, co-opting opinion leaders, educational enterprises and academia in their marketing campaign.
Off label promotion
Off-label use of gabapentin for psychiatric off-label use also resulted in convictions. Although some small, non-controlled studies in the 1990s — mostly sponsored by gabapentin's manufacturer — suggested that gabapentin treatment for bipolar disorder may be promising, other more recent and better controlled studies have found it to be no more effective (and in one study, slightly less effective) than placebo. Subsequent to the corporate acquisition of the original patent holder, the pharmaceutical company Pfizer admitted that there had been violations of FDA guidelines regarding the promotion of unproven off-label uses for gabapentin in the Franklin v. Pfizer case. In addition, the FDA black box warning states: "Antiepileptic drugs (AEDs), including Neurontin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication."
Despite this controversy, many psychiatrists continue to prescribe it for a variety of off-label purposes. Oftentimes, it is tried as an alternative treatment when patients are unable to tolerate the side effects of more proven mood stabilizers such as lithium. More frequently, it is prescribed on a speculative basis as an auxiliary treatment, when single-drug therapy has consistently failed to yield sufficient positive results.
Reuters reported on March 25, 2010 that "Pfizer Inc... violated federal racketeering law by improperly promoting the epilepsy drug Neurontin... Under federal RICO law... the penalty is automatically tripled, so the finding will cost Pfizer $141 million." The case stems from a claim from Kaiser Foundation Health Plan Inc. that "it was misled into believing Neurontin was effective for off-label treatment of migraines, bipolar disorder and other conditions. Pfizer argued that Kaiser physicians still recommend the drug for those uses."
Bloomberg News (3/26/10, Voris, Lawrence) added that "during the trial, Pfizer argued that Kaiser doctors continued to prescribe the drug even after the health insurer sued Pfizer in 2005. The insurer's website also still lists Neurontin as a drug for neuropathic pain, Pfizer lawyers said in closing argument."
The Wall Street Journal (3/26/10, Kamp) noted that Pfizer spokesman Christopher Loder said, "We are disappointed with the verdict and will pursue post-trial motions and an appeal." "The verdict and the judge's rulings are not consistent with the facts and the law," he added, according to Reuters (3/26/10, Berkrot).
Franklin v. Pfizer case
By some estimates, off-label prescriptions account for roughly 90% of Neurontin sales. While off-label prescriptions are common for a number of drugs and are perfectly legal (if not always appropriate), marketing of off-label uses of a drug is strictly illegal. In 2004, Warner-Lambert agreed to plead guilty and pay $430 million in fines to settle civil and criminal charges regarding the illegal marketing of Neurontin for off-label purposes, and further legal action is pending. The courts of New York State, for example, have refused to certify a class of injured parties who took Neurontin for off-label use, finding that they had failed to state that they had any injury.
The University of California, San Francisco (UCSF) has archived and studied the documents made public by this case, which opens a unique window into the illegal promotion and marketing of pharmaceuticals. However, Pfizer maintains that the illegal activity originated in 1996, well before it acquired Parke-Davis (through its acquisition of Warner-Lambert) in 2000. Several lawsuits are underway after people who had been prescribed gabapentin for off-label treatment of bipolar disorder later attempted or committed suicide.
Although gabapentin is not a controlled substance, it does produce psychoactive effects that cause it to have potential for recreational use. Even in low doses, gabapentin causes sensations of reduced acute pain, reduced anxiety and even a tendency to become overly social and talkative. Larger doses can cause the user to become numb and even fully insensate. Although it is widely regarded as having little or no potential for misuse, it is often a misused drug in Canadian Northern communities and among inmates in California State prisons. However, Pregabalin, a subsequent Pfizer spin-off, is a controlled substance under Schedule V of the United States' Controlled Substances Act.
Gabapentin is also used for some animal treatments, but formulations (especially liquid forms) for human use may contain the sweetener Xylitol which is toxic to dogs, so care must be taken if the human version is used for veterinary purposes.
- ^ "Gabapentin". The American Society of Health-System Pharmacists. http://www.drugs.com/monograph/gabapentin.html. Retrieved 3 April 2011.
- ^ Vedula, SS; Bero, L, Scherer, RW, Dickersin, K (2009-11-12). "Outcome reporting in industry-sponsored trials of gabapentin for off-label use.". The New England journal of medicine 361 (20): 1963–71. doi:10.1056/NEJMsa0906126. PMID 19907043.
- ^ Moore, RA; Wiffen, PJ, Derry, S, McQuay, HJ (2011-03-16). "Gabapentin for chronic neuropathic pain and fibromyalgia in adults.". Cochrane database of systematic reviews (Online) (3): CD007938. doi:10.1002/14651858.CD007938.pub2. PMID 21412914.
- ^ Ho, KY; Gan, TJ, Habib, AS (2006-12-15). "Gabapentin and postoperative pain--a systematic review of randomized controlled trials.". Pain 126 (1-3): 91–101. doi:10.1016/j.pain.2006.06.018. PMID 16846695.
- ^ Bar Ad, V (2010 Sep). "Gabapentin for the treatment of cancer-related pain syndromes.". Reviews on recent clinical trials 5 (3): 174–8. PMID 20482492.
- ^ Phillips, TJ; Cherry, CL, Cox, S, Marshall, SJ, Rice, AS (2010-12-28). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.". PloS one 5 (12): e14433. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3010990.
- ^ Wiffen, P; Collins, S, McQuay, H, Carroll, D, Jadad, A, Moore, A (2005-07-20). "Anticonvulsant drugs for acute and chronic pain.". Cochrane database of systematic reviews (Online) (3): CD001133. doi:10.1002/14651858.CD001133.pub2. PMID 16034857.
- ^ Mulleners, WM; Chronicle, EP (2008 Jun). "Anticonvulsants in migraine prophylaxis: a Cochrane review.". Cephalalgia : an international journal of headache 28 (6): 585–97. PMID 18454787.
- ^ Finnerup, NB; Sindrup SH, Jensen TS (2010 Sep). "The evidence for pharmacological treatment of neuropathic pain". Pain 150 (3): 573–81. doi:10.1016/j.pain.2010.06.019. PMID 20705215.
- ^ Tran de, QH; Duong S, Bertini P, Finlayson RJ. (2010 Feb). "Treatment of complex regional pain syndrome: a review of the evidence.". Can J Anaesth. (57(2)): 149–66.. PMID 20054678.
- ^ Johannessen, SI; Ben-Menachem, E (2006). "Management of focal-onset seizures: an update on drug treatment.". Drugs 66 (13): 1701–25. PMID 16978035.
- ^ French, JA; Kanner, AM, Bautista, J, Abou-Khalil, B, Browne, T, Harden, CL, Theodore, WH, Bazil, C, Stern, J, Schachter, SC, Bergen, D, Hirtz, D, Montouris, GD, Nespeca, M, Gidal, B, Marks WJ, Jr, Turk, WR, Fischer, JH, Bourgeois, B, Wilner, A, Faught RE, Jr, Sachdeo, RC, Beydoun, A, Glauser, TA, American Academy of Neurology Therapeutics and Technology Assessment, Subcommittee, American Academy of Neurology Quality Standards, Subcommittee, American Epilepsy Society Quality Standards, Subcommittee, American Epilepsy Society Therapeutics and Technology Assessment, Subcommittee (2004 May). "Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.". Epilepsia 45 (5): 401–9. doi:10.1111/j.0013-9580.2004.06204.x. PMID 15101821.
- ^ Wilby, J; Kainth, A, Hawkins, N, Epstein, D, McIntosh, H, McDaid, C, Mason, A, Golder, S, O'Meara, S, Sculpher, M, Drummond, M, Forbes, C (2005 Apr). "Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.". Health technology assessment (Winchester, England) 9 (15): 1–157, iii-iv. PMID 15842952.
- ^ McLean, RJ; Gottlob, I (2009 Aug). "The pharmacological treatment of nystagmus: a review.". Expert opinion on pharmacotherapy 10 (11): 1805–16. PMID 19601699.
- ^ Strupp, M; Brandt, T (2009 Jul). "Current treatment of vestibular, ocular motor disorders and nystagmus.". Ther Adv Neurol Disord. (4): 223-39. PMID 21179531.
- ^ Toulis, KA; Tzellos, T, Kouvelas, D, Goulis, DG (2009 Feb). "Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis.". Clinical therapeutics 31 (2): 221–35. PMID 19302896.
- ^ "Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review.". Arch Gynecol Obstet. 276 ((5):): 463–9. Epub 2007 Jun 26. Nov; 2007. PMID 17593379.
- ^ a b c Mack, Alicia (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy 9 (6): 559–68. PMID 14664664. http://www.amcp.org/data/jmcp/Contemporary%20Subject-559-568.pdf. Retrieved 2006-08-14.
- ^ Martínez-Raga, J; Sabater, A; Perez-Galvez, B; Castellano, M; Cervera, G (May 2004). "Add-on gabapentin in the treatment of opiate withdrawal". Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (3): 599–601. doi:10.1016/j.pnpbp.2003.11.020. PMID 15093968.
- ^ Sood, A; Ebbert JO, Schroeder DR, Croghan IT, Sood R, Vander Weg MW, Wong GY, Hays JT (February 2007). "Gabapentin for smoking cessation: a preliminary investigation of efficacy". Nicotine & tobacco research 9 (2): 291–8. doi:10.1080/14622200601080307. PMID 17365760.
- ^ Sood, A; Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, Hays JT (March 2010). "Gabapentin for smoking cessation". Nicotine & tobacco research 12 (3): 300–4. doi:10.1093/ntr/ntp195. PMC 2825098. PMID 20081039. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2825098.
- ^ Chouinard, G (May 2006). "The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs". J Psychiatry Neurosci 31 (3): 168–176. ISSN 1180-4882. PMC 1449873. PMID 16699602. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1449873.
- ^ Frye, Mark A.; et al. (2000). "A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders" (Abstract). Journal of Clinical Psychopharmacology 20 (6): 607–14. doi:10.1097/00004714-200012000-00004. PMID 11106131. http://www.psychopharmacology.com/pt/re/jclnpsychopharm/abstract.00004714-200012000-00004.htm. Retrieved 2006-08-14.
- ^ a b Kristy Monson "Does Neurontin Cause Weight Gain? http://epilepsy.emedtv.com/neurontin/neurontin-and-weight-gain.html
- ^ Piccirillo, JF; Finnell J, Vlahiotis A, Chole RA, Spitznagel E (2007). "Relief of idiopathic subjective tinnitus: is gabapentin effective?". Arch Otolaryngol Head Neck Surg 133 (4): 390–7. doi:10.1001/archotol.133.4.390. PMID 17438255.
- ^ a b "Neurontin packaging insert" (pdf). U.S. Food and Drug Administration (FDA). 2009-05-01. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020235s041,020882s028,021129s027lbl.pdf. Retrieved 2010-07-16.
- ^ Lasso-de-la-Vega, MC; Zapater, P; Such, J; Perez-Mateo, M; Horga, JF (December 2001). "Gabapentin-associated hepatotoxicity". Am J Gastroenterol 96 (12): 3460–2. doi:10.1111/j.1572-0241.2001.05357.x. PMID 11774985.
- ^ http://www.fdable.com/advanced_aers_query/0b20534305c9d0e50552a188af4a3487
- ^ Dogukan, A; Aygen, B; Berilgen, MS; Dag, S; Bektas, S; Gunal, AI (April 2006). "Gabapentin-induced coma in a patient with renal failure". Hemodialysis International 10 (2): 168–9. doi:10.1111/j.1542-4758.2006.00089.x. PMID 16623669.
- ^ Bookwalter, T; Gitlin, M (December 2005). "Gabapentin-induced neurologic toxicities". Pharmacotherapy 25 (12): 1817–9. doi:10.1592/phco.2005.25.12.1817. PMID 16305301.
- ^ Gabapentin Official FDA information, side effects and uses
- ^ Patorno E, Bohn RL, Wahl PM, et al. (April 2010). "Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death". JAMA 303 (14): 1401–9. doi:10.1001/jama.2010.410. PMID 20388896.
- ^ "Suicidal Behavior and Ideation and Antiepileptic Drugs". U.S. Food and Drug Administration (FDA). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm.
- ^ Fisk MC; Feeley J; O'Reilly C (2009-07-24). "Pfizer Faces First Trial on Neurontin Suicide Claim". Bloomberg Markets. http://www.bloomberg.com/apps/news?pid=20601127&sid=a1CYnBA5tGV4. Retrieved 2010-07-16.
- ^ a b c Tran KT, Hranicky D, Lark T, Jacob Nj (June 2005). "Gabapentin withdrawal syndrome in the presence of a taper". Bipolar Disorders 7 (3): 302–4. doi:10.1111/j.1399-5618.2005.00200.x. PMID 15898970.
- ^ Kruszewski SP, Paczynski RP, Kahn DA (July 2009). "Gabapentin-induced delirium and dependence". Journal of Psychiatric Practice 15 (4): 314–9. doi:10.1097/01.pra.0000358318.73684.df. PMID 19625887.
- ^ Finch CK, Eason J, Usery JB (September 2010). "Gabapentin withdrawal syndrome in a post-liver transplant patient". Journal of Pain & Palliative Care Pharmacotherapy 24 (3): 236–8. doi:10.3109/15360288.2010.493927. PMID 20718643.
- ^ a b Barrueto F, Green J, Howland MA, Hoffman RS, Nelson LS (2002). "Gabapentin withdrawal presenting as status epilepticus". Journal of Toxicology. Clinical Toxicology 40 (7): 925–8. PMID 12507063.
- ^ Hellwig TR, Hammerquist R, Termaat J (June 2010). "Withdrawal symptoms after gabapentin discontinuation". American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists 67 (11): 910–2. doi:10.2146/ajhp090313. PMID 20484214.
- ^ R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 677–8. ISBN 978-0-9626523-7-0.
- ^ Eroglu, Çagla; Allen, Nicola J.; Susman, Michael W.; O'Rourke, Nancy A.; Park, Chan Young; Özkan, Engin; Chakraborty, Chandrani; Mulinyawe, Sara B. et al. (2009-10-08), "Gabapentin Receptor α2δ-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis", Cell 139 (2): 380–392, doi:10.1016/j.cell.2009.09.025, PMC 2791798, PMID 19818485, http://www.cell.com/abstract/S0092-8674%2809%2901185-4
- ^ Hendrich, J; Van Minh, AT; Heblich, F.; Nieto-Rostro, M; Watschinger, K; Striessnig, J; Wratten, J; Davies, A et al. (March 2008). "Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin". Proc. Natl. Acad. Sci. U.S.A. 105 (9): 3628–33. Bibcode 2008PNAS..105.3628H. doi:10.1073/pnas.0708930105. PMC 2265195. PMID 18299583. http://www.pnas.org/content/105/9/3628.full.pdf.
- ^ Davies, A; Hendrich, J; Van Minh, AT; Wratten, J; Douglas, L; Dolphin, AC (May 2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels". Trends Pharmacol Sci 28 (5): 220–8. doi:10.1016/j.tips.2007.03.005. PMID 17403543.
- ^ Baillie, JK; Power, I (January 2006). "The mechanism of action of gabapentin in neuropathic pain". Curr Opin Investig Drugs 7 (1): 33–9. ISSN 1472-4472. PMID 16425669.
- ^ David F. McAuley, Pharm.D. How does pregabalin compare to gabapentin in the treatment of neuropathic pain? GlobalRPh Inc.
- ^ Jensen B, Regier LD, editors. RxFiles : Drug comparison charts. 7th ed. Saskatoon, SK: RxFiles, 2010; p.78
- ^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. doi:10.1007/s11095-011-0490-x. PMID 21681607.
- ^ Sotelo J. "Regulation of Clinical Research Sponsored by Pharmaceutical Companies: A Proposal.". PLoS Med 3(7):: e306.. doi:10.1371/journal.pmed.0030306.
- ^ Pfizer agrees record fraud fine
- ^ Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Ann. Intern. Med. 145 (4): 305–7. PMID 16908923. http://www.annals.org/cgi/content/full/145/4/305?etoc. Retrieved December 2, 2009.
- ^ "Warner–Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion" (Press release). US Department of Justice. May 13, 2004. http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm. Retrieved December 2, 2009.
- ^ Mathew NT, Rapoport A, Saper J, et al. (February 2001). "Efficacy of gabapentin in migraine prophylaxis". Headache 41 (2): 119–28. doi:10.1046/j.1526-4610.2001.111006119.x. PMID 11251695.
- ^ Pfizer: Product MonographPDF (251 KB) Retrieved 14 August 2006
- ^ a b Steinman, MA; Bero LA, Chren MM, Landefeld CS. (2006-08-15). "Narrative review: the promotion of gabapentin: an analysis of internal industry documents.". Ann Intern Med. 145 (4): 284–293.. PMID 16908919.
- ^ [lieffcabraser.com/media/pnc/0/media.750.pdf Saris Decision]. lieffcabraser.com/media/pnc/0/media.750.pdf.
- ^ Pande, AC; Crockatt JG, Janney CA, Werth JL, Tsaroucha G. (2000). "Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy" (Abstract). Bipolar Disorders 2 (3 Pt 2): 249–55. doi:10.1034/j.1399-5618.2000.20305.x. PMID 11249802.
- ^ http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
- ^ Baldessarini, Ross J.; Leahy L, Arcona S, Gause D, Zhang W, Hennen J. (2007). "Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders" (Abstract). Psychiatric Serv[ices] 58 (58): 85–91. doi:10.1176/appi.ps.58.1.85.
- ^ Berkrot, Bill (2010-03-25). "US jury's Neurontin ruling to cost Pfizer $141 mln". Reuters. http://www.reuters.com/article/2010/03/25/pfizer-neurontin-idUSN259778920100325.
- ^ Tansey, Bernadette (2004-05-14). "Huge penalty in drug fraud, Pfizer settles felony case in Neurontin off-label promotion.". San Francisco Chronicle. p. C-1. http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/05/14/BUGKK6L0LB1.DTL.
- ^ Jane E. Henney, MD (15 August 2006). "Editorial: Safeguarding Patient Welfare: Who's In Charge?". Annals of Internal Medicine 145 (4): 305–307. PMID 16908923. http://www.annals.org/cgi/content/full/145/4/305?etoc. Retrieved 2006-08-14.
- ^ Baron v. Pfizer, Inc., 2007 N.Y. Slip Op. 05813 (App. N.Y., July 5, 2007)
- ^ Drug Industry Document Archive
- ^ Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents - Steinman et al. 145 (4): 284 - Annals of Internal Medicine
- Gabapentin information from MedlinePlus
- Gabapentin PubMed Health. National Center for Biotechnology Information (NCBI)
- News Article regarding Neurontin settlement and off-label marketing/use
- Website for the pending Class Action Lawsuit against Pfizer
- U.S. FDA information on safety of antiepileptics
- Bloomberg News on Neurontin lawsuit
- U.S. National Library of Medicine: Drug Information Portal - Gabapentin
- Erowid Gabapentin Vault
Analgesics (N02A, N02B) Opioids
See also: Opioids templateOpium & alkaloids thereofSemi-synthetic opium
Pyrazolones Cannabinoids Anilides Non-steroidal
See also: NSAIDs templatePropionic acid classOxicam classAcetic acid classAnthranilic acid
Meclofenamate • Mefenamic acidSalicylates
Atypical, adjuvant and potentiators,
Metabolic agents and miscellaneousAmitryptiline • Befiradol • Bicifadine • Carisoprodol • Camphor • Cimetidine • Clonidine • Chlorzoxazone • Cyclobenzaprine • Duloxetine • Esreboxetine • Flupirtine • Gabapentin • Glafenine • Hydroxyzine • Ketamine • Menthol • Mephenoxalone • Methocarbamol • Nefopam • Orphenadrine • Pregabalin • Proglumide • Scopolamine • Tebanicline • Trazodone • Gabapentin enacarbil • Ziconotide
Anticonvulsants (N03) GABAA receptor agonist Other GABA agents Carbonic anhydrase inhibitor Channel blockersPrimarily sodiumPrimarily calciumUnknown/ungrouped Channel openersPotassiumRetigabine Indirect GABA agents Unknown/multiple/
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III
Mood stabilizers Mood disorder (F30–F39, 296) History Symptoms Spectrum TreatmentOther mood stabilizersNon-pharmaceutical Related
Wikimedia Foundation. 2010.